Hermann S, Klein S A, Jacobi V, Thalhammer A, Bialleck H, Duchscherer M, Wassmann B, Hoelzer D, Martin H
Department of Haematology and Oncology, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.
Br J Haematol. 2001 May;113(2):446-54. doi: 10.1046/j.1365-2141.2001.02747.x.
Leukaemic patients with advanced disease and severe fungal infections as well as older patients with substantial co-morbidity are usually excluded from conventional allotransplantation because of increased morbidity and mortality. We approached allogeneic transplantation in four patients with a median age of 62 years (one chronic myeloid leukaemia in blast crisis, one high-risk acute myeloid leukaemia (AML) in first complete remission (CR1), one AML in 2nd relapse, one AML in CR2 with pre-existing fungal lung infections (two aspergillus, two mucor) and additional co-morbidity (diabetes n = 2, aortic aneurysm n = 1, arterial sclerosis n = 2) by combining non-myeloablative conditioning with an intensified supportive care regimen, including amphotericin B and 4-12 (median 9) prophylactic granulocyte transfusions from granulocyte colony-stimulating factor (G-CSF)-stimulated volunteer donors. G-CSF was also given to patients until neutrophil recovery. All four patients recovered to a neutrophil count of 0.5 x 109/l after a median of 11.5 d (range 11-13 d). Prophylactic granulocyte transfusions also reduced the need for platelet transfusions and minimized mucositis. All patients were discharged at a median of 25 d (range 18-59 d) and are alive and well after a median follow-up of > 390 d (range 336-417 d) without evidence of leukaemia. Regression of the fungal lesions was documented in three patients, with a slight progression detected by computerized tomography scan of the chest in one patient. We conclude that pulmonary fungal infections are not a contraindication for allogeneic stem cell transplantation, if non-myeloablative conditioning regimens are used in combination with granulocyte transfusions, intravenous amphotericin B and G-CSF.
患有晚期疾病和严重真菌感染的白血病患者以及合并症严重的老年患者,由于发病率和死亡率增加,通常被排除在传统同种异体移植之外。我们对4例中位年龄为62岁的患者进行了异基因移植(1例慢性髓性白血病急变期、1例首次完全缓解(CR1)的高危急性髓性白血病(AML)、1例AML第二次复发、1例CR2期AML合并既往肺部真菌感染(2例曲霉菌、2例毛霉菌)以及其他合并症(糖尿病n = 2、主动脉瘤n = 1、动脉硬化n = 2)),方法是将非清髓性预处理与强化支持治疗方案相结合,包括两性霉素B以及来自粒细胞集落刺激因子(G-CSF)刺激的志愿供者的4 - 12次(中位9次)预防性粒细胞输注。患者也接受G-CSF治疗直至中性粒细胞恢复。4例患者在中位11.5天(范围11 - 13天)后中性粒细胞计数恢复至0.5×10⁹/L。预防性粒细胞输注也减少了血小板输注的需求并使黏膜炎最小化。所有患者中位25天(范围18 - 59天)出院,中位随访> 390天(范围336 - 417天)后均存活且情况良好,无白血病证据。3例患者的真菌病灶出现消退,1例患者胸部计算机断层扫描显示有轻微进展。我们得出结论,如果采用非清髓性预处理方案并联合粒细胞输注、静脉注射两性霉素B和G-CSF,肺部真菌感染并非同种异体干细胞移植的禁忌证。